Sen. Bernie Sanders. (Photo: Rick Koppstein/ALM Media)
Congressional scrutiny of drug prices continued to heat up on Thursday, with three pharmaceutical executives taking the hot seat before a Senate panel. The CEOs of Merck, Bristol Myers Squibb and Johnson & Johnson faced a barrage of questions from members of the Health, Education, Labor and Pensions committee.
"The overwhelming beneficiary of high drug prices in America is the pharmaceutical industry," committee Chair Bernie Sanders, I-Vt., said. "The United States government does not regulate drug companies. With a few exceptions, the drug companies regulate the United States government."
Continue Reading for Free
Register and gain access to:
- Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
